U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 20

1.

Tanshinone I inhibit normal and malignant hematopoiesis by repressing EZH2 activity [human]

(Submitter supplied) Purpose: To explore the mechanism of how Tan I inhibits malignant hematopoiesis at the gene expression level Methods: NB4 cells treated with DMSO or Tan I 10 μM were collected for RNA sequencing Results: We found that 376 genes were differentially expressed between DMSO and Tan I treatment in the NB4 cells (p value <=0.05, |log2 fold change| >= 0.25) Conclusions: We identified MMP9 and ABCG2 as two possible downstream genes of Tan I’s effects on EZH2
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL24676
6 Samples
Download data: CSV
2.

Tanshinone I inhibit normal and malignant hematopoiesis by repressing EZH2 activity

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Danio rerio; Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platforms:
GPL24995 GPL24676
12 Samples
Download data
Series
Accession:
GSE155574
ID:
200155574
3.

Tanshinone I inhibit normal and malignant hematopoiesis by repressing EZH2 activity [zebrafish]

(Submitter supplied) Purpose: To explore the mechanism of how Tan I inhibits malignant hematopoiesis at the gene expression level Methods: 72 hpf Tg(c-mybhyper: GFP) zebrafish embryos treated with DMSO or Tan I 60 μM were collected for RNA sequencing Results: We found that 1882 genes were differentially expressed between DMSO and Tan I treatment in c-mybhyper fish embryos (p value <=0.05, |log2 fold change| >= 0.25) Conclusions: We identified MMP9 and ABCG2 as two possible downstream genes of Tan I’s effects on EZH2
Organism:
Danio rerio
Type:
Expression profiling by high throughput sequencing
Platform:
GPL24995
6 Samples
Download data: CSV
Series
Accession:
GSE155573
ID:
200155573
4.

Transcriptome analysis for KDM6A mutated urothelial bladder carcinoma and EZH2 inhibitor treated KDM6A mutated urothelial bladder carcinoma

(Submitter supplied) Purpose: The goals of this study are to compare 1. The transcription profile in KDM6A wildtype and KDM6A mutated urothelial bladder carcinoma. 2. The transcriptional changes in KDM6A mutated urothelial bladder carcinoma upon EZH2 inhibitor treatment.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL11154
50 Samples
Download data: TXT
Series
Accession:
GSE92723
ID:
200092723
5.

High-throughput deep sequence of zebrafish wild-type and ezh2 mutant embryos

(Submitter supplied) To determine the molecular basis for the reduced blood cells in circulation in ezh2 mutant zebrafish, we performed high-throughput sequencing at 28 hpf. Results revealed 893 up-regulated genes and 425 down-regulated genes in the ezh2 mutant zebrafish compared with wild-type zebrafish. We found that some hematopoietic genes are down-regulated in ezh2 mutant zebrafish, which was reconfirmed with qRT-PCR.
Organism:
Danio rerio
Type:
Expression profiling by high throughput sequencing
Platform:
GPL18413
2 Samples
Download data: TXT
Series
Accession:
GSE103913
ID:
200103913
6.

The Polycomb Repressive Complex 2 Is Required For MLL-AF9 Leukemia

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Mus musculus
Type:
Expression profiling by array; Genome binding/occupancy profiling by high throughput sequencing
Platforms:
GPL13112 GPL1261
23 Samples
Download data: CEL, WIG
Series
Accession:
GSE34963
ID:
200034963
7.

Epigenetic profiling of WT and Ezh2-null MLL-AF9 murine leukemic cells

(Submitter supplied) Chromatin immunoprecipitation (ChIP) for H3K27me3 followed by Solexa sequencing in WT and Ezh2-null leukemic cells from primary and secondary recipients.
Organism:
Mus musculus
Type:
Genome binding/occupancy profiling by high throughput sequencing
Platform:
GPL13112
4 Samples
Download data: WIG
Series
Accession:
GSE34962
ID:
200034962
8.

Expression profiling of secondary wild type (WT) and Ezh2-null murine MLL-AF9 AML

(Submitter supplied) We evaluated gene expression changes in secondary recipient murine leukemia caused by retroviral overexpression of MLL-AF9. We compared wild-type (WT) leukemia cells with mutant leukemia cells after cre-mediated inactivation of a homozygous conditional allele for Ezh2, a component of the Polycomb Repressive Complex2.
Organism:
Mus musculus
Type:
Expression profiling by array
Platform:
GPL1261
9 Samples
Download data: CEL, TXT
Series
Accession:
GSE34961
ID:
200034961
9.

Expression profiling of primary wild type (WT), Ezh2-null and Eed-null murine MLL-AF9 AML

(Submitter supplied) We evaluated gene expression changes in murine leukemia caused by retroviral overexpression of MLL-AF9. We compared wild-type (WT) leukemia cells with mutant leukemia cells after cre-mediated inactivation of homozygous conditional alleles for Ezh2 or Eed, both of which are components of the Polycomb Repressive Complex2.
Organism:
Mus musculus
Type:
Expression profiling by array
Platform:
GPL1261
10 Samples
Download data: CEL, TXT
Series
Accession:
GSE34959
ID:
200034959
10.

Epigenetic pattern after EZH1,2 inhibition in lymohoma cells

(Submitter supplied) Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy for H3K27me3-high malignancies harboring EZH2WT/WT has yet been established. We explored epigenome and transcriptome in EZH2WT/WT aggressive lymphomas, and found that mutual interference and compensatory function of co-expressed EZH1 and EZH2 rearrange their own genome-wide distribution, thereby establishing restricted chromatin and gene expression signatures. more...
Organism:
Homo sapiens
Type:
Genome binding/occupancy profiling by genome tiling array
Platform:
GPL19784
117 Samples
Download data: TXT, XLSX
Series
Accession:
GSE138342
ID:
200138342
11.

Expression analysis after EZH1,2 inhibition in lymohoma cells

(Submitter supplied) To define gene expression alteration by EZH1/2 ihibition, we performed gene expression profiling in lymphoma cells after treatment of inhibitors or shRNAs
Organism:
Homo sapiens
Type:
Expression profiling by array
Platforms:
GPL21185 GPL13497
42 Samples
Download data: TXT
Series
Accession:
GSE138282
ID:
200138282
12.

Gene expression of extranodal NK/T cell lymphoma

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6883
53 Samples
Download data
Series
Accession:
GSE80632
ID:
200080632
13.

Gene expression of extranodal NK/T cell lymphoma II

(Submitter supplied) Gene expression profiling of extranodal nasal-type NK/T cell lymphoma and other EBV-associated lymphoid proliferation disease patients was analyzed to elucidate association between JAK-STAT pathway and canonical or non-canonical PRC2/EZH2 target pathways using Illumina HumanRef-8 v3 chips.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6883
47 Samples
Download data
Series
Accession:
GSE80631
ID:
200080631
14.

Gene expression of extranodal NK/T cell lymphoma I

(Submitter supplied) Gene expression profiling of extranodal nasal-type NK/T cell lymphoma and other EBV-associated lymphoid proliferation disease patients was analyzed to elucidate association between JAK-STAT pathway and canonical or non-canonical PRC2/EZH2 target pathways using Illumina HumanRef-8 v3 chips.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6883
6 Samples
Download data
Series
Accession:
GSE80629
ID:
200080629
15.

Expression data from NKYS transfected with siRNAs or plasmids

(Submitter supplied) The siRNA transfection includes JAK3 and EZH2 siRNAs. The plasmid transfection includes EZH2 WT and its mutants. We used gene expression data from JAK3 siRNA to test whether it affected epigenetic regulation, and used EZH2 mutants to study how it affected EZH2 canonical function.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6244
17 Samples
Download data: CEL
Series
Accession:
GSE75680
ID:
200075680
16.

Transcriptomes change differerntly in differernt cancer cells upon EPZ-6438 treatment

(Submitter supplied) Purpose: The goals of this study are to compare NGS-derived transcriptome profiling (RNA-seq) to find out the difference between EZH2 inhibitor treatment and DMSO group in each cancer cell line, and find the relationship between transcriptomes change and drug sensivitity. Methods: mRNA profiles of cell lines were generated using Illumina PE150, then GSEA was used for cellular pathways analysis Results: The result showed 53 common oncogenic signatures were enriched in RNA-seq data. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL11154
18 Samples
Download data: XLS
Series
Accession:
GSE119088
ID:
200119088
17.

Genome-wide Profiling of H3K27ac binding in human cancer cell lines

(Submitter supplied) Upregulation of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) and its associated histone H3 lysine 27 (H3K27) trimethylation frequently occur in human cancer, yet both preclinical and clinical evidence suggested the very limited benefit of EZH2-targeted therapies. This study investigated the underlying mechanisms from a perspective of EZH2 inhibition-caused histone modification crosstalk. more...
Organism:
Homo sapiens
Type:
Genome binding/occupancy profiling by high throughput sequencing
Platform:
GPL18573
9 Samples
Download data: BW
Series
Accession:
GSE119086
ID:
200119086
18.

Atheroprotective flow alters EZH2/H3K27me3 dependent transcriptional profile in human endothelial cells

(Submitter supplied) Atherosclerosis is a focal disease that preferentially develop in the regions of atheroprone disturbed flow, but less in regions of atheroprotective laminar flow. The mechanisms by which atheroprotective laminar flow prevents atherosclerosis at the epigenetic level remain largely unknown. In this study, we observed that laminar flow decreased histone methyltransferase EZH2, which imposes a repressive epigenetic mark of histone 3 lysine 27 trimethylation (H3K27me3) onto target gene promoters, leading to transcriptional silencing. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL16791
10 Samples
Download data: TXT
19.

EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens; Mus musculus
Type:
Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing
Platforms:
GPL16791 GPL17021
38 Samples
Download data: BED, BW
Series
Accession:
GSE85390
ID:
200085390
20.

EZH2 inhibition as a targeted therapy for H3K27M mutant pediatric gliomas [RNA-Seq]

(Submitter supplied) Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive brain tumour that is located in the pons and primarily affects children. Whole-exome sequencing studies have identified recurrent driver mutations in H3F3A and HIST1H3B, leading to the expression of histone H3 in which lysine 27 is substituted with methionine (H3K27M) in nearly 80% of DIPGs. H3K27M inhibits Polycomb Repressive Complex 2 (PRC2) activity by binding to its catalytic subunit EZH2 and although DIPGs with H3K27M mutation show global loss of H3 with trimethylated lysine 27 (H3K27me3), several genomic loci are still H3K27me3 positive. more...
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL13112
8 Samples
Download data: BW
Series
Accession:
GSE71387
ID:
200071387
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=4|blobid=MCID_67506b0c51e3a106b45d14f6|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center